Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19008144 | 0.92 | MAP4K4 (0.49) | MAP4K4CCR3CCR5HRH3 | |
| SCHEMBL18626531 | 0.83 | KDM4E (0.49) | MAP4K4CYP2D6HRH3 | |
| SCHEMBL15587588 | 0.82 | MAP4K4 (0.50) | MAP4K4CCR3PARP1CYP2D6HRH1 | |
| SCHEMBL17896303 | 0.79 | MAP4K4 (0.53) | MAP4K4CCR3 | |
| SCHEMBL18626504 | 0.79 | LMNA (0.46) | MAP4K4CYP2D6TNKS | |
| SCHEMBL14924037 | 0.79 | ALDH1A1 (0.50) | PARP1TNKSHRH3 | |
| SCHEMBL18626467 | 0.78 | MAP4K4 (0.49) | MAP4K4HRH3 | |
| SCHEMBL18626533 | 0.77 | MAP4K4 (0.50) | MAP4K4CYP2D6 | |
| SCHEMBL21709586 | 0.77 | ABL1 (0.41) | MAP4K4CYP2D6KCNH2CCR5 | |
| SCHEMBL15587584 | 0.75 | MAP4K4 (0.50) | MAP4K4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885CCR3 313/4885PARP1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.